Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Update

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 149,700 shares, a growth of 6.0% from the November 30th total of 141,200 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average trading volume of 16,500 shares, the short-interest ratio is currently 9.1 days.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on EPRX shares. Rodman & Renshaw started coverage on Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th.

Eupraxia Pharmaceuticals Stock Down 1.3 %

NASDAQ:EPRX opened at $3.13 on Friday. Eupraxia Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $5.58. The stock’s fifty day moving average is $3.14 and its two-hundred day moving average is $2.78. The stock has a market capitalization of $85.39 million and a price-to-earnings ratio of -4.35.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.